This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsBuy This Stock About Cara Therapeutics Stock (NASDAQ:CARA) 30 days 90 days 365 days Advanced Chart Get Cara Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$13.29▼$17.1052-Week Range N/AVolume237,144 shsAverage Volume22,224 shsMarket Capitalization$24.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read More Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CARA Stock News HeadlinesThis ‘Strong Buy’ Stock Could Be the Next Big Biotech BreakoutJuly 18, 2025 | msn.comCara Therapeutics, Inc.: Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi TherapeuticsApril 16, 2025 | finanznachrichten.de“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning. | InvestorPlace (Ad)Tvardi Therapeutics Announces Closing of Merger with Cara TherapeuticsApril 15, 2025 | globenewswire.comCara Therapeutics board approves 1-for-3 reverse stock splitApril 15, 2025 | markets.businessinsider.comCara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment SoarsApril 14, 2025 | msn.comCara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi TherapeuticsApril 14, 2025 | globenewswire.comCARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARAFebruary 20, 2025 | businesswire.comSee More Headlines CARA Stock Analysis - Frequently Asked Questions How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.72) by $3.60. The biopharmaceutical company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%. When did Cara Therapeutics' stock split? Cara Therapeutics's stock reverse split before market open on Wednesday, April 16th 2025.The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA). Company Calendar Last Earnings8/14/2024Today8/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARA CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.51 million Net Margins-1,099.76% Pretax Margin-1,099.76% Return on Equity-367.97% Return on Assets-107.43% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.71 Sales & Book Value Annual Sales$7.14 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$12.58 per share Price / BookN/AMiscellaneous Outstanding Shares4,574,000Free Float4,429,000Market Cap$24.33 million OptionableOptionable Beta0.41 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CARA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.